Manufacturing Techniques of Orally Dissolving Films - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Manufacturing Techniques of Orally Dissolving Films
The manufacture of orally dissolving films is done by various methods such as solvent casting, hot-melt extrusion, semisolid casting, solid-dispersion extrusion, and rolling. The authors discuss these methods and the various parameters in which dissolving films are evaluated.


Pharmaceutical Technology
Volume 35, Issue 1, pp. 70-73

Clinical and regulatory requirement

To indicate bioequivalency of a product to that of existing oral drug, an abbreviated new drug application is required. In-vitro dissolution studies and therapeutic equivalence are considered. Comparative bioequivalence between an orally disintegrating tablet and an ODF can be evaluated. If the ODF exhibits a different target pharmacokinetic profile compared with the existing marketed product, the ODF is considered a new dosage form. For a new dosage form, a new clinical study is required. A new clinical study offers the advantage of three years of marketing exclusivity to the product. Preclinical toxicity studies are not required if the molecule is the same as that of the approved product. Safety, tolerability, and efficacy features are to be demonstrated in such trials. Oral mucosa-irritation testing is carried out in both animal models and humans. The hamster-cheek pouch is the most appropriate model for predicting irritation criteria before testing in humans (12).

Conclusion

ODFs are a possible alternative dosage form to orally disintegrating tablets. These films offer the benefits of pleasant mouthfeel and rapid disintegration in the mouth. Solvent casting, hot-melt extrusion, semisolid casting, solid-dispersion extrusion, and rolling are important manufacturing methods to produce these films.

Renuka Mishra* is an assistant professor, and Avani Amin is a professor in the Department of Pharmaceutics and Pharmaceutical Technology, the Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India, Sarkhej-Gandhinagar Highway, Ahmedabad, Gujarat, India,

*To whom all correspondence should be addressed.

References

1. S. Borsadia, D. O'Halloran, and J.L. Osborne, Drug Del. Tech. 3 (3), 63–66 (2003).

2. T. Ghosh and W.Pfister, "Intraoral Delivery Systems: An Overview, Current Status and Future Trends," in Drug Delivery to the Oral Cavity: Molecules to Market, T. Ghosh and W. Pfister, Eds. (Taylor & Francis, Florida, CRC Press, 2005), pp. 1–34.

3. P. V. Arnum, "Outsourcing Solid Dosage Manufacturing," Pharm. Technol. 30 (6), 44–52 (2006).

4. R. Mishra and A. Amin, Pharm. Technol. Eur. 19 (10), 35–39 (2007).

5. M. Repka et al., "Hot Melt Extrusion," in Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J. Boylan, Eds. (Marcel Dekker Inc., New York, Vol. 2, 2nd Edition, 2002), pp. 1488–1504.

6. M.A. Repka and J.W. McGinity, Pharm. Dev. Technol. 6 (3), 297–304 (2001).

7. M. Repka and J.W. McGinity, J. Controlled Release 76 (3), 341–351 (2001).

8. J. Breitenbach, Eur. J. Pharm. Biopharm. 54 (2), 107–117 (2002).

9. A. Arya et al., Int. J. Chem. Tech. Research 2 (1), 578–583 (2010).

10. Gole et al., "Pharmaceutical and Other Dosage Forms," US Patent 5648093, Jul. 1997.

11. R.K. Yang et al., "Thin Film with Non-Self Aggregating Uniform Heterogeneity and Drug Delivery Systems Made Therefrom," US Patent Application 20080226695.

12. R. Mishra and A. Amin, Pharm. Technol. 33 (2), 48–56 (2009).

13. R.P. Dixit, S.P. Puthli, J. Controlled Release 139 (2), 94–107 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here